A Registry for Patients Taking Uptravi (SPHERE)
Uptravi® (SelexiPag): tHe usErs dRug rEgistry
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Guaynabo, Puerto Rico, 00917
- CardioPulmonary Research, PSC
-
-
-
-
Alabama
-
Mobile, Alabama, United States, 36617
- University of South Alabama
-
-
Arizona
-
Phoenix, Arizona, United States, 85006
- Pulmonary Associates
-
Phoenix, Arizona, United States, 85027
- Cardioivascular Consultants, Ltd.
-
Tucson, Arizona, United States, 85724
- University of Arizona-Clinical Translational and Regenerative Medicine
-
-
California
-
La Jolla, California, United States, 92093
- University of California San Diego
-
Los Angeles, California, United States, 90033
- University of Southern California
-
Los Angeles, California, United States, 90073
- VA Greater Los Angeles Healthcare Center
-
San Francisco, California, United States, 94143
- UCSF Medical Center
-
Santa Barbara, California, United States, 93105
- Santa Barbara Cottage Hospital
-
Torrance, California, United States, 90502
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- University of Colorado
-
Denver, Colorado, United States, 80206
- National Jewish Health
-
Greeley, Colorado, United States, 80631
- Banner Health Research Institute
-
-
Florida
-
Celebration, Florida, United States, 34747
- Florida Lung Asthma and Sleep Specialists
-
Fort Lauderdale, Florida, United States, 33316
- Broward Pulmonary and Sleep
-
Gainesville, Florida, United States, 32610
- University of Florida, HSC
-
Hudson, Florida, United States, 34667
- West Pasco Pulmonary Associates
-
Jacksonville, Florida, United States, 32209
- University of Florida-Jacksonville College of Medicine
-
Orlando, Florida, United States, 32803
- Central Florida Pulmonary Group
-
Tampa, Florida, United States, 33606
- University of South Florida
-
Weston, Florida, United States, 33331
- Cleveland Clinic Florida
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Emory University School of Medicine
-
Marietta, Georgia, United States, 30060
- Wellstar Marietta Pulmonary Medicine
-
-
Illinois
-
Chicago, Illinois, United States, 60637
- University of Chicago Hospitals
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Indiana University Health
-
Indianapolis, Indiana, United States, 46260
- St. Vincent Medical Group, Inc.
-
-
Iowa
-
Clive, Iowa, United States, 50325
- CIC Associates
-
Iowa City, Iowa, United States, 52242
- University of Iowa Hospitals and Clinics
-
-
Kentucky
-
Louisville, Kentucky, United States, 40202
- University of Louisville
-
Louisville, Kentucky, United States, 40202
- Norton Pulmonary Specialists
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70112
- LSU Health Sciences Center
-
New Orleans, Louisiana, United States, 70121
- Oschner Clinic Foundation/Oschner Medical Center
-
-
Maine
-
South Portland, Maine, United States, 04106
- Chest Medicine Associates
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- University of Maryland
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
Boston, Massachusetts, United States, 02111
- Tufts University Medical Center
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan
-
Lansing, Michigan, United States, 48912
- Sparrow Clinical Research Institute
-
Troy, Michigan, United States, 48085
- William Beaumont Hospital
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55407
- Minneapolis Heart Institute Foundation
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University School of Medicine
-
Saint Louis, Missouri, United States, 63141
- Mercy Research, Mercy Hospital Saint Louis
-
-
Nebraska
-
Lincoln, Nebraska, United States, 68510
- Somnos Clinical Research
-
Omaha, Nebraska, United States, 68198
- University of Nebraska Medical Center
-
-
New Jersey
-
Newark, New Jersey, United States, 07112
- Newark Beth Israel Medical Center
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87131
- University of New Mexico
-
-
New York
-
Fayetteville, New York, United States, 13066
- Pulmonary Health Physicians, PC
-
Mineola, New York, United States, 11501
- Winthrop University Hospital
-
New Hyde Park, New York, United States, 11040
- Northwell Health
-
New York, New York, United States, 10032
- Columbia University Medical Center
-
New York, New York, United States, 10029
- Mount Sinai Hospital
-
New York, New York, United States, 10065
- Weil Cornell Medicine
-
Stony Brook, New York, United States, 11794
- Stony Brook University Medical Center
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- University of North Carolina Hospitals at Chapel Hill
-
Durham, North Carolina, United States, 27710
- Duke University Medical Center
-
-
Ohio
-
Cincinnati, Ohio, United States, 45267
- University of Cincinnati
-
Cincinnati, Ohio, United States, 45219
- The Lindner Research Center at The Christ Hospital
-
Cleveland, Ohio, United States, 44195
- Cleveland Clinic Foundation
-
Middleburg Heights, Ohio, United States, 44130
- Southwest General Health Center
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Oregon Health & Science University
-
Portland, Oregon, United States, 97210
- Legacy Medical Group-Pulmonary and Sleep Clinic
-
-
Pennsylvania
-
Doylestown, Pennsylvania, United States, 18901
- Doylestown Health Cardiology
-
Philadelphia, Pennsylvania, United States, 19104
- University of Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19140
- Temple University Hospital
-
Pittsburgh, Pennsylvania, United States, 15212
- Allegheny General Hospital
-
Pittsburgh, Pennsylvania, United States, 15213
- University of Pittsburgh School of Medicine
-
York, Pennsylvania, United States, 17402
- York Hospital
-
-
Rhode Island
-
Providence, Rhode Island, United States, 02903
- Rhode Island Hospital
-
-
South Carolina
-
Anderson, South Carolina, United States, 29621
- AnMed Health Medical Center
-
Charleston, South Carolina, United States, 29425
- Medical University of South Carolina
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Vanderbilt University Medical Center
-
-
Texas
-
Dallas, Texas, United States, 75390
- University of Texas Southwestern Medical Center
-
Dallas, Texas, United States, 75246
- Baylor Scott and White Health
-
Houston, Texas, United States, 77030
- Houston Methodist Hospital
-
Houston, Texas, United States, 77030
- University of Texas, Houston Health Center
-
San Antonio, Texas, United States, 78229
- Methodist Healthcare of San Antonio
-
-
Virginia
-
Charlottesville, Virginia, United States, 22908
- University of Virginia Health System
-
Falls Church, Virginia, United States, 22042
- Inova Fairfax
-
Norfolk, Virginia, United States, 23507
- Sentara Cardiovascular Research Institute
-
-
Washington
-
Spokane, Washington, United States, 99204
- Providence Health & Services d/b/a/ Providence Sacred Heart Medical Center & Children's Hospital Providence Medical Research Center
-
Tacoma, Washington, United States, 98405
- MultiCare Institute for Research & Innovation
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53705
- University of Wisconsin School of Medicine and Public Health
-
Milwaukee, Wisconsin, United States, 53150
- Medical College of Wisconsin/Froedtert Hospital
-
Milwaukee, Wisconsin, United States, 53215
- Aurora Research Institute / Aurora St. Luke's Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Signed patient informed consent form (ICF).
- Patients ≥ 18 years of age at time of Uptravi initiation, and
Patients who initiate Uptravi:
- at enrollment, or
- less than or equal to 60 days prior to enrollment and have a documented titration regimen (defined as all documented dose changes including, but not limited to: starting dose and dates and highest tolerated dose and dates)
Exclusion Criteria:
- Patients previously exposed to Uptravi treatment during a clinical trial.
- Patients that previously discontinued Uptravi for any reason, prior to study enrollment (discontinuation defined as an interruption of therapy greater than or equal to 30 days).
- Patients enrolled in a blinded clinical trial or in a clinical trial involving an unapproved drug.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Group/Cohort Information
This is a US multi-center, prospective, real world, observational drug registry enrolling patients actively treated with Uptravi.
Participating patients will be followed prospectively for a maximum of 18 months from the date of enrollment into the registry.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Using Electronic Medical Records, the change in Hemodynamics (by Right Heart Catherization), WHO FC and 6 Minute Walk Distance (by meters) from diagnosis to registry enrollment and to EOS will be measured/collected.
Time Frame: Followed prospectively for a maximum of 18 months from the date of enrollment into the registry.
|
To describe demographics and disease characteristics of patients treated with Uptravi.
|
Followed prospectively for a maximum of 18 months from the date of enrollment into the registry.
|
|
The initial dose (in micrograms), dose at selected intervals (in days), highest dose, maintenance dose, time between titrations, time from initiation to maintenance dose (in days) and total duration of exposure to Uptravi (in days) will be collected.
Time Frame: Followed prospectively for a maximum of 18 months from the date of enrollment into the registry.
|
To describe the dosing regimens and titration of Uptravi, including any transition from other PAH specific therapies to Uptravi and from Uptravi to other prostanoids.
|
Followed prospectively for a maximum of 18 months from the date of enrollment into the registry.
|
|
Occurrence of AEs and SAEs (incl. hospitalizations), discontinuation of Uptravi and reason for stopping and occurrence of all-cause death by relationship to PAH.
Time Frame: Followed prospectively for a maximum of 18 months from the date of enrollment into the registry.
|
To describe the clinical course of patients treated with Uptravi.
|
Followed prospectively for a maximum of 18 months from the date of enrollment into the registry.
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Actelion, Actelion
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- AC-065A402
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Arterial Hypertension
-
NCT07612657Not yet recruitingPulmonary Arterial Hypertension | Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH) | Pulmonary Arterial Hypertension (PAH) | Pulmonary Arterial Hypertension WHO Group I | Pulmonary Arterial Hypertension PAH
-
NCT07217522RecruitingPulmonary Arterial Hypertension | Pulmonary Hypertension | Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH) | Pulmonary Arterial Hypertension of Congenital Heart Disease | Pulmonary Arterial Hypertension Associated With Schistosomiasis (Disorder) | Pulmonary Arterial and Chronic Thromboembolic Pulmonary Hypertension | Pulmonary Arterial Hypertension Associated With Connective Tissue Disease (Disorder) | Pulmonary Arterial Hypertension Associated With Connective Tissue Disease
-
NCT07632898Not yet recruitingPulmonary Arterial Hypertension (PAH)
-
NCT07266519Not yet recruiting
-
NCT07601295Not yet recruitingPulmonary Arterial Hypertension (PAH)
-
NCT07457762RecruitingPulmonary Arterial Hypertension (PAH)
-
NCT07357974Not yet recruitingPulmonary Arterial Hypertension (PAH)
-
NCT07177703Not yet recruitingPulmonary Arterial Hypertension (PAH)
-
NCT07487441Not yet recruitingPulmonary Hypertension | Pulmonary Arterial Hypertension (PAH)
-
NCT03069716CompletedPulmonary Arterial Hypertension | Idiopathic Pulmonary Arterial Hypertension | Associated Pulmonary Arterial Hypertension | Heritable Pulmonary Arterial Hypertension